全文获取类型
收费全文 | 196146篇 |
免费 | 18625篇 |
国内免费 | 7514篇 |
专业分类
耳鼻咽喉 | 1194篇 |
儿科学 | 4624篇 |
妇产科学 | 2686篇 |
基础医学 | 37213篇 |
口腔科学 | 3777篇 |
临床医学 | 12345篇 |
内科学 | 33468篇 |
皮肤病学 | 3245篇 |
神经病学 | 16075篇 |
特种医学 | 3718篇 |
外国民族医学 | 57篇 |
外科学 | 14315篇 |
综合类 | 24137篇 |
现状与发展 | 30篇 |
预防医学 | 8863篇 |
眼科学 | 2297篇 |
药学 | 26029篇 |
21篇 | |
中国医学 | 6774篇 |
肿瘤学 | 21417篇 |
出版年
2024年 | 504篇 |
2023年 | 3090篇 |
2022年 | 6322篇 |
2021年 | 7994篇 |
2020年 | 6750篇 |
2019年 | 7746篇 |
2018年 | 7344篇 |
2017年 | 7245篇 |
2016年 | 7088篇 |
2015年 | 8515篇 |
2014年 | 11867篇 |
2013年 | 13254篇 |
2012年 | 12193篇 |
2011年 | 14451篇 |
2010年 | 12287篇 |
2009年 | 11654篇 |
2008年 | 11055篇 |
2007年 | 9850篇 |
2006年 | 8909篇 |
2005年 | 7591篇 |
2004年 | 6647篇 |
2003年 | 5644篇 |
2002年 | 4377篇 |
2001年 | 3731篇 |
2000年 | 3085篇 |
1999年 | 2801篇 |
1998年 | 2402篇 |
1997年 | 2178篇 |
1996年 | 1883篇 |
1995年 | 1583篇 |
1994年 | 1380篇 |
1993年 | 1163篇 |
1992年 | 969篇 |
1991年 | 867篇 |
1990年 | 714篇 |
1989年 | 599篇 |
1988年 | 513篇 |
1987年 | 415篇 |
1986年 | 422篇 |
1985年 | 796篇 |
1984年 | 820篇 |
1983年 | 574篇 |
1982年 | 644篇 |
1981年 | 508篇 |
1980年 | 418篇 |
1979年 | 365篇 |
1978年 | 280篇 |
1977年 | 221篇 |
1976年 | 206篇 |
1975年 | 142篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
《Journal of thoracic oncology》2020,15(1):138-143
IntroductionEGFR mutated (EGFRm) NSCLC tumors occasionally express programmed cell death ligand 1 (PD-L1), although frequency and clinical relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical outcomes following treatment with osimertinib or comparator EGFR tyrosine kinase inhibitors in the FLAURA trial (phase III, NCT02296125).MethodsOf 231 tissue blocks available from the screened population (including EGFRm-positive and -negative samples), 197 had sufficient tissue for PD-L1 testing using the SP263 (Ventana, Tucson, Arizona) immunohistochemical assay. Tumor cell (TC) staining thresholds of PD-L1 TC greater than or equal to 1%, TC greater than or equal to 25%, and TC greater than or equal to 50% were applied. Progression-free survival (PFS) was investigator-assessed, per Response Evaluation Criteria in Solid Tumor, version 1.1, according to PD-L1 expressors (TC ≥ 1%) or negatives (TC < 1%) in randomized patients.ResultsPD-L1 staining was successful in 193 of 197 patient formalin-fixed paraffin-embedded blocks; of these, 128 of 193 were EGFRm-positive and 106 of 128 patients were randomized to treatment (osimertinib: 54; comparator: 52). At the PD-L1 TC greater than or equal to 25% threshold, 8% (10 of 128) of EGFRm-positive tumors expressed PD-L1 versus 35% (23 of 65) of EGFRm-negative tumors. With the TC greater than or equal to 1% threshold, 51% (65 of 128) versus 68% (44 of 65) were mutation-positive and –negative, respectively, and with the TC greater than or equal to 50% threshold, 5% (7 of 128) versus 28% (18 of 65), were mutation-positive and -negative, respectively. For PD-L1 expressors (TC ≥ 1%), median PFS was 18.4 months with osimertinib and 6.9 months with comparator (hazard ratio = 0.30; 95% confidence interval: 0.15–0.60). For PD-L1–negative patients (TC < 1%), median PFS was 18.9 months with osimertinib and 10.9 months with comparator (hazard ratio = 0.37; 95% confidence interval: 0.17–0.74).ConclusionsClinical benefit with osimertinib was unaffected by PD-L1 expression status. 相似文献
93.
《European journal of medical genetics》2020,63(6):103919
Neuronal growth regulator 1 (NEGR1), a member of the immunoglobulin superfamily cell adhesion molecule subgroup IgLON, has been involved in neuronal growth and connectivity. Genetic variants, in or near the NEGR1 locus, have been associated with obesity and, more recently, with learning difficulties, intellectual disability, and psychiatric disorders.Here, we described the only second report of NEGR1 gene disruption in 1p31.1 microdeletion in two patients. Patient 1 is a 14-year-old female with neurological and psychiatric features present also in her family. Patient 2 is a 5-month-old infant showing global hypotonia as unique neurological features till now. This patient also carries 7p22.1 duplication, of paternal origin, that could be responsible for some malformations present in the child.We hypothesize a role of NEGR1 in producing the phenotype of our patients and compare them with other cases previously reported in the literature and DECIPHER database to better identify a possible genotype-phenotype correlation. 相似文献
94.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
95.
96.
目的 探讨类风湿关节炎患者外周血miR-150-5p、细胞因子信号抑制因子1(suppressor of cytokine signaling 1,SOCS1)mRNA的表达及对类风湿关节炎(Rheumatoid Arthritis,RA)疾病诊断、中医证型判断的意义。方法 纳入符合诊断标准的RA患者57例及健康对照组19例,根据《22个专业95个病种中医诊疗方案》有关RA的中医证候诊断标准,判断RA的中医证型。qPCR检测RA患者及健康对照组miR-150-5p、SOCS1mRNA的相对表达水平,同时检测血常规、肝功能、肾功能等常规指标。双荧光素酶分析方法判断两者是否存在靶向关系。统计分析miR-150-5p、SOCS1 mRNA对RA疾病的诊断意义及其与中医证型的相关性。结果 RA患者外周血miR-150-5p的相对表达水平下调,低于正常人群(t = -19.019,P < 0.05);其表达水平随疾病活动度升高,有下降趋势;患者外周血SOCS1 mRNA的相对表达水平上调,低于正常人群(t = 5.333,P < 0.05);其表达水平随疾病活动度升高,有上升趋势。MiR-150-5p与SOCS1 mRNA有靶向结合关系(P < 0.05)。通过AUC曲线比较,miR-150-5p的相对表达水平区分RA的敏感性及特异性分别为98.1%、92.1%(AUC = 0.972,P < 0.05);SOCS1 mRNA的相对表达水平无法区分RA(AUC = 0.472,P > 0.05)。RA患者中miR-150-5p的相对表达水平低于3.06,RA患者风湿痹阻证、寒湿痹阻证的相对风险分别为8.33、250.00(P < 0.05)。结论 miR-150-5p、SOCS1 mRNA在RA患者中有差异性表达,且有靶向结合关系。miR-150-5p可能是RA的疾病诊断及中医风湿痹阻证、寒湿痹阻证证型诊断的潜在生物标志物。 相似文献
97.
目的:总结富亮氨酸胶质瘤失活1蛋白(LGI1)抗体阳性边缘性脑炎的临床和影像特点及诊疗预后。
方法:报道我院1例LGI1抗体阳性相关边缘性脑炎并文献复习。结果:患者女性,60岁,表现为渐进性加重
的记忆力减退、癫痫发作(全身强直阵挛发作,面-臂肌张力障碍发作)、低钠血症和轻度精神行为异常。颅 脑MRI-T2/Flair序列提示双侧颞叶(左侧为甚)内侧、海马异常高信号。脑脊液抗LGI1抗体阳性(++)。经激
素治疗症状有所改善。检索既往报道LGI1抗体阳性边缘性脑炎患者237例,多数呈急性、亚急性起病,最
常见是记忆障碍、癫痫(含面-臂肌张力障碍发作)和低钠血症,头颅MRI(特别是MRI-T2/Flair序列)显示单
侧或者双侧海马区、颞叶异常多见,早期免疫治疗预后良好。结论:LGI1抗体阳性相关边缘性脑炎有其特
有的临床特点,免疫治疗可明显改善患者预后。 相似文献
98.
《Cancer cell》2021,39(11):1497-1518.e11
- Download : Download high-res image (282KB)
- Download : Download full-size image
99.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(8):e461-e467
IntroductionVon Willebrand factor (vWF) cleaving protease ADAMTS-13 has a key role for maintaining normal size of vWF. A deficiency or dysfunction of vWF cleaving protease is associated with ultra large vWF multimers and thrombotic microangiopathy. Patients with cancers have reduced levels of vWF cleaving protease. In this pilot study, we have evaluated whether or not deficiencies of ADAMTS-13 were present in myelodysplastic syndromes (MDS). Moreover, we assessed if a reduction in basal levels of ADAMTS-13 may play a role in the prognosis of MDS.Patients and MethodsWe measured and compared the levels of vWF cleaving protease ADAMTS-13 in 100 patients with MDS and 35 healthy controls. Patients were divided into 2 groups according to the International Prognostic Scoring System: group I consisting of 44 patients with low-risk MDS and group II of 56 patients with high-risk MDS. Patients with high-risk and low-risk MDS presented significantly lower levels of ADAMTS-13 than controls (P < .001 and P = .0177, respectively). High-risk patients had significantly lower levels of ADAMTS-13 when compared with the low-risk group (P < .001).ResultsWe found that reduced levels of ADAMTS-13 have a relationship with overall survival (P < .001). Statistical analysis showed that ADAMTS-13 correlates with cytogenetics (P < .001) and a tendency of slight correlation with platelet count and basal levels of ADAMTS-13 (R, 0.35; P value, 0.001). Moreover, we found that levels of ADAMTS-13 have correlation with response to treatment (P < .001).ConclusionsADAMTS-13 in MDS might represent a surrogate marker of prognosis, response to therapy, or disease progression. Further studies are needed. 相似文献
100.
- Download : Download high-res image (66KB)
- Download : Download full-size image